Colorectal Disease最新文献

英文中文

Complex ventral hernia repair using botulinum toxin with combination of Fasciotens® after colorectal surgery: A video vignette 结直肠术后应用肉毒杆菌毒素联合Fasciotens®修复复杂腹疝：视频短片。

IF 2.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Colorectal Disease

Pub Date : 2026-01-14 DOI: 10.1111/codi.70374

Semra Demirli Atici, Yasemin Yildirim, Aras Emre Canda, Mustafa Cem Terzi, Cigdem Arslan, İlknur Erenler Bayraktar, Onur Bayraktar, Tayfun Bisgin

引用次数: 0

A randomized phase III trial of structured tumour response surveillance and shared decision-making for organ preservation in rectal cancer – PRODIGE 101-GRECCAR 20-EVAREC trial protocol 一项结构化肿瘤反应监测和共同决策用于直肠癌器官保存的随机III期试验- PRODIGE 101- grecar 20-EVAREC试验方案。

IF 2.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Colorectal Disease

Pub Date : 2026-01-14 DOI: 10.1111/codi.70371

Barbara Noiret, Véronique Vendrely, Alexis Delattre, Adrien Vavasseur, Hélène Maillou-Martinaud, Stéphanie Nougaret, Jérémie Jacques, Thibaud Haaser, Côme Lepage, Quentin Denost

Aim

Standard management with chemoradiotherapy (CRT) or total neoadjuvant therapy (TNT) followed by total mesorectal excision (TME) reduces local recurrence but often is associated with significant long-term functional impairment. Organ preservation (OP) has become a key therapeutic goal in rectal cancer to reduce surgery-related morbidity without compromising oncological outcomes. Three main OP strategies have been developed: Watch and Wait (W&W) strategy, Local Excision (LE) and Contact X-ray Brachytherapy (CXB), both applicable in patients showing a favourable tumour response after neoadjuvant therapy. The current challenge is defining the optimal timing and modalities for response assessment to accurately identify complete clinical response while balancing oncological control, functional outcomes and patient preferences. This trial evaluates whether a structured tumour response surveillance program combined with shared decision-making (SDM) can safely increase OP rates.

Methods

GRECCAR 20 is a multicentre, randomized, open-label, phase III trial enrolling patients with cT2-T3N0-1 rectal adenocarcinoma ≤ 8 cm from the anal verge and ≤ 4 cm in length, without involvement of the anal canal. Across the French GRECCAR and PRODIGE network, 270 patients will be recruited over 36 months. After neoadjuvant treatment (CRT or induction chemotherapy followed by CRT), participants are randomized to either a structured tumour response surveillance strategy with SDM over 8 to 24 weeks (experimental arm) or standard response assessment without SDM at 8 weeks (control arm). In the experimental arm (Arm A), reassessments at 2-, 4- and 6-month post-treatment will guide management decisions—W&W, LE, CXB or TME—through a collaborative process between patient and clinician. In the control arm (Arm B), treatment decisions at 2 months will be made solely by the clinician, between LE or TME, based on clinical, endoscopic and radiological assessment. The primary outcome is the OP rate at 2 years. Secondary endpoints include disease-free survival, TME-free survival, functional outcomes, quality of life (QoL) and patient-reported outcome measures (PROMs).

Conclusion

GRECCAR 20 is the first randomized trial to assess a structured tumour response surveillance program incorporating SDM in rectal cancer. By prioritizing patient values and QoL, this trial aims to improve OP rates without compromising oncological safety, potentially establishing a new standard of personalized, patient-centred care.

目的：放化疗（CRT）或全新辅助治疗（TNT）后全肠系膜切除术（TME）的标准治疗可减少局部复发，但通常伴有严重的长期功能损害。器官保存（OP）已成为直肠癌的关键治疗目标，以减少手术相关的发病率而不影响肿瘤预后。已有三种主要的OP策略：观察和等待（W&W）策略、局部切除（LE）和接触x射线近距离治疗（CXB），这两种策略都适用于新辅助治疗后肿瘤反应良好的患者。目前的挑战是确定反应评估的最佳时机和模式，以准确识别完整的临床反应，同时平衡肿瘤控制、功能结果和患者偏好。该试验评估了结构化肿瘤反应监测计划与共享决策（SDM）相结合是否可以安全地增加OP率。方法：grecar 20是一项多中心、随机、开放标签的III期临床试验，纳入cT2-T3N0-1型直肠腺癌患者，这些患者距离肛门边缘≤8cm，长度≤4cm，未累及肛管。通过法国grecar和PRODIGE网络，将在36个月内招募270名患者。在新辅助治疗（CRT或诱导化疗后再进行CRT）后，参与者被随机分配到8至24周的SDM结构化肿瘤反应监测策略（实验组）或8周无SDM的标准反应评估（对照组）。在实验组（A组），通过患者和临床医生之间的协作过程，在治疗后2、4和6个月的重新评估将指导管理决策——w&w、LE、CXB或tme。在对照组（B组），2个月时的治疗决定将完全由临床医生根据临床、内窥镜和放射学评估在LE或TME之间做出。主要结果是2年的手术成功率。次要终点包括无病生存期、无tme生存期、功能结局、生活质量（QoL）和患者报告的结局指标（PROMs）。结论：GRECCAR 20是首个评估结合SDM的结构化肿瘤反应监测项目的随机试验。通过优先考虑患者价值和生活质量，该试验旨在在不影响肿瘤安全性的情况下提高手术成功率，有可能建立一个个性化的、以患者为中心的护理新标准。

{"title":"A randomized phase III trial of structured tumour response surveillance and shared decision-making for organ preservation in rectal cancer – PRODIGE 101-GRECCAR 20-EVAREC trial protocol","authors":"Barbara Noiret, Véronique Vendrely, Alexis Delattre, Adrien Vavasseur, Hélène Maillou-Martinaud, Stéphanie Nougaret, Jérémie Jacques, Thibaud Haaser, Côme Lepage, Quentin Denost","doi":"10.1111/codi.70371","DOIUrl":"10.1111/codi.70371","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Standard management with chemoradiotherapy (CRT) or total neoadjuvant therapy (TNT) followed by total mesorectal excision (TME) reduces local recurrence but often is associated with significant long-term functional impairment. Organ preservation (OP) has become a key therapeutic goal in rectal cancer to reduce surgery-related morbidity without compromising oncological outcomes. Three main OP strategies have been developed: Watch and Wait (W&W) strategy, Local Excision (LE) and Contact X-ray Brachytherapy (CXB), both applicable in patients showing a favourable tumour response after neoadjuvant therapy. The current challenge is defining the optimal timing and modalities for response assessment to accurately identify complete clinical response while balancing oncological control, functional outcomes and patient preferences. This trial evaluates whether a structured tumour response surveillance program combined with shared decision-making (SDM) can safely increase OP rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>GRECCAR 20 is a multicentre, randomized, open-label, phase III trial enrolling patients with cT2-T3N0-1 rectal adenocarcinoma ≤ 8 cm from the anal verge and ≤ 4 cm in length, without involvement of the anal canal. Across the French GRECCAR and PRODIGE network, 270 patients will be recruited over 36 months. After neoadjuvant treatment (CRT or induction chemotherapy followed by CRT), participants are randomized to either a structured tumour response surveillance strategy with SDM over 8 to 24 weeks (experimental arm) or standard response assessment without SDM at 8 weeks (control arm). In the experimental arm (Arm A), reassessments at 2-, 4- and 6-month post-treatment will guide management decisions—W&W, LE, CXB or TME—through a collaborative process between patient and clinician. In the control arm (Arm B), treatment decisions at 2 months will be made solely by the clinician, between LE or TME, based on clinical, endoscopic and radiological assessment. The primary outcome is the OP rate at 2 years. Secondary endpoints include disease-free survival, TME-free survival, functional outcomes, quality of life (QoL) and patient-reported outcome measures (PROMs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>GRECCAR 20 is the first randomized trial to assess a structured tumour response surveillance program incorporating SDM in rectal cancer. By prioritizing patient values and QoL, this trial aims to improve OP rates without compromising oncological safety, potentially establishing a new standard of personalized, patient-centred care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10512,"journal":{"name":"Colorectal Disease","volume":"28 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145970749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Laparoscopic sigmoid colectomy for idiopathic sigmoid colonic varices: A rare case report and literature review: A video vignette 腹腔镜乙状结肠切除术治疗特发性乙状结肠静脉曲张：一例罕见病例报告及文献回顾：一个视频片段。

IF 2.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Colorectal Disease

Pub Date : 2026-01-14 DOI: 10.1111/codi.70369

Sreeram Seshadri, Balasubramanian SwarnaPradha, Janak Malu, Srinivaasan Mani, Sivakumar Srivatsan Gurumurthy, Palanisamy Senthilnathan, Chinnusamy Palanivelu

引用次数: 0

Recurrent left-sided diverticulitis after surgery: A systematic review and single arm meta-analysis 手术后复发性左侧憩室炎：一项系统综述和单臂荟萃分析。

IF 2.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Colorectal Disease

Pub Date : 2026-01-12 DOI: 10.1111/codi.70368

Richard Sassun, Francesco Brucchi, Annaclara Sileo, Barbara Vignati, Jacopo Crippa, Pietro Achilli, Dario Maggioni, Antonino Spinelli, Isacco Montroni, Alexander T. Hawkins, Giulio Mari

Introduction

Recurrent diverticulitis after resection remains a key concern despite advances in minimally invasive surgery. These recurrences may result from incomplete resection of the diseased segment, unrecognized synchronous diverticulosis or ongoing alterations in colonic motility and microbiome composition. This systematic review and single-arm meta-analysis aimed to estimate long-term recurrence and stoma rates following elective surgery for left-sided diverticulitis.

Methods

Following PRISMA guidelines and PROSPERO registration, PubMed, Cochrane and Scopus databases were searched (2000–2025) for studies reporting recurrence after elective resection. Single-arm meta-analysis of proportions was performed using random-effects models. Quality was assessed using the JBI Checklist, while subgroup and sensitivity analyses explored heterogeneity. A comparative meta-analysis with medical treatment was not performed due to selection bias, crossover and lack of standardized non-operative protocols.

Results

Twenty-four studies (7,525 patients; mean follow-up 53 months) were included. Pooled recurrence rate was 6.2% (95% CI: 4.8–8.0%; I² = 80.6%), with no difference between RCTs (6.3%) and observational studies (6.1%) or complicated vs. uncomplicated disease. Stoma rate (16 studies, 6,400 patients) was 17.1% (95% CI: 8.4–31.9%; I² = 99.3%), significantly higher in complicated (31.0%) than uncomplicated (5.5%) cases (p = 0.009) and significantly lower post-2020 (8.0% vs. 31.2%; p = 0.003). Quality was high in 92% of studies, while sensitivity analyses confirmed robustness.

Conclusions

Surgical resection achieves durable control with low recurrence and stoma rates. Research priorities include standardized definitions of recurrence, assessing long-term QOL and exploring microbiome influences to refine patient selection and minimize residual risk.

导论：尽管微创手术取得了进展，但憩室炎切除术后复发仍然是一个关键问题。这些复发可能是由于病变部分切除不完全，未被识别的同步憩室病或结肠运动和微生物组成的持续改变。本系统综述和单臂荟萃分析旨在评估左侧憩室炎择期手术后的长期复发和造口率。方法：按照PRISMA指南和PROSPERO注册，检索PubMed、Cochrane和Scopus数据库（2000-2025），查找报告择期切除后复发的研究。采用随机效应模型对比例进行单臂meta分析。使用JBI检查表评估质量，亚组分析和敏感性分析探讨异质性。由于选择偏倚、交叉和缺乏标准化的非手术方案，没有进行与药物治疗的比较荟萃分析。结果：纳入24项研究（7525例患者，平均随访53个月）。合并复发率为6.2% (95% CI: 4.8-8.0%; I2 = 80.6%)，随机对照试验（6.3%）与观察性研究（6.1%）、并发症与非并发症之间无差异。造口率（16项研究，6400例患者）为17.1% (95% CI: 8.4 ~ 31.9%, I2 = 99.3%)，并发症组（31.0%）显著高于无并发症组（5.5%）（p = 0.009）， 2020年后组（8.0% vs. 31.2%, p = 0.003）显著低于并发症组（8.0% vs. 31.2%）。92%的研究质量高，敏感性分析证实了稳健性。结论：手术切除获得持久的控制，复发率和造口率低。研究重点包括标准化复发定义，评估长期生活质量和探索微生物组的影响，以优化患者选择和最小化剩余风险。

{"title":"Recurrent left-sided diverticulitis after surgery: A systematic review and single arm meta-analysis","authors":"Richard Sassun, Francesco Brucchi, Annaclara Sileo, Barbara Vignati, Jacopo Crippa, Pietro Achilli, Dario Maggioni, Antonino Spinelli, Isacco Montroni, Alexander T. Hawkins, Giulio Mari","doi":"10.1111/codi.70368","DOIUrl":"10.1111/codi.70368","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Recurrent diverticulitis after resection remains a key concern despite advances in minimally invasive surgery. These recurrences may result from incomplete resection of the diseased segment, unrecognized synchronous diverticulosis or ongoing alterations in colonic motility and microbiome composition. This systematic review and single-arm meta-analysis aimed to estimate long-term recurrence and stoma rates following elective surgery for left-sided diverticulitis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Following PRISMA guidelines and PROSPERO registration, PubMed, Cochrane and Scopus databases were searched (2000–2025) for studies reporting recurrence after elective resection. Single-arm meta-analysis of proportions was performed using random-effects models. Quality was assessed using the JBI Checklist, while subgroup and sensitivity analyses explored heterogeneity. A comparative meta-analysis with medical treatment was not performed due to selection bias, crossover and lack of standardized non-operative protocols.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-four studies (7,525 patients; mean follow-up 53 months) were included. Pooled recurrence rate was 6.2% (95% CI: 4.8–8.0%; <i>I</i><sup>2</sup> = 80.6%), with no difference between RCTs (6.3%) and observational studies (6.1%) or complicated vs. uncomplicated disease. Stoma rate (16 studies, 6,400 patients) was 17.1% (95% CI: 8.4–31.9%; <i>I</i><sup>2</sup> = 99.3%), significantly higher in complicated (31.0%) than uncomplicated (5.5%) cases (<i>p</i> = 0.009) and significantly lower post-2020 (8.0% vs. 31.2%; <i>p</i> = 0.003). Quality was high in 92% of studies, while sensitivity analyses confirmed robustness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Surgical resection achieves durable control with low recurrence and stoma rates. Research priorities include standardized definitions of recurrence, assessing long-term QOL and exploring microbiome influences to refine patient selection and minimize residual risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10512,"journal":{"name":"Colorectal Disease","volume":"28 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In my hands, in my theatre, in spite of evidence—The implementation gap in surgery 在我的手中，在我的手术室里，尽管有证据——外科手术的实施差距。

IF 2.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Colorectal Disease

Pub Date : 2026-01-11 DOI: 10.1111/codi.70372

Arabella Scantlebury, Amy Grove

引用次数: 0

Methodological considerations in evaluating D3 lymph node dissection for nonagenarian colon cancer patients 评价老年结肠癌患者D3淋巴结清扫的方法学考虑。

IF 2.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Colorectal Disease

Pub Date : 2026-01-10 DOI: 10.1111/codi.70366

Tian Ruan, Minghang Li, Yue Huang, Hui Wang, Ping Zhu, Zhengrun Yang

引用次数: 0

Contemporary neoadjuvant strategies for rectal cancer: The GRECCAR snapshot study 当代直肠癌新辅助治疗策略：GRECCAR快照研究

IF 2.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Colorectal Disease

Pub Date : 2026-01-10 DOI: 10.1111/codi.70358

Antoine Cazelles, Quentin Denost, Benjamin Fernandez, Michel Rivoire, Hélène Meillat, Philippe Rouanet, Mehdi Karoui, Adeline Germain, Leon Maggiori, Alain Valverde, Nicolas Peru, Eddy Cotte, Etienne Buscail, Jeremie H. Lefevre, Bertrand Trilling, Jean Luc Faucheron, Pierre Yves Sage, Laura Beyer-Berjot, Stephane Benoist, Arnaud Alves, Charles Sabbagh, Jean-Jacques Tuech, Julien Coget, Frédéric Marchal, Guillaume Meurette, Diane Mège, Dahbia Djelil, Simone Manfredelli, Aurélien Venara, Mehdi Ouaissi, Gilles Manceau, French Research Group of Rectal Cancer Surgery (GRECCAR)

Aim

Neoadjuvant treatment for rectal cancer has evolved markedly with the growing adoption of total neoadjuvant therapy (TNT), organ-preservation strategies and selective omission of radiotherapy. Recent trials support risk-based personalization, but its application in real-world settings remains poorly documented. The aim was to describe current neoadjuvant treatment practices for mid-low rectal cancer in French expert centres and identify tumour- and patient-related factors influencing decisions.

Method

This observational study included patients with non-metastatic rectal adenocarcinoma ≤10 cm from the anal verge, discussed in tumour boards (October 2022 to March 2023) across GRECCAR centres. Tumours were classified as early, intermediate-risk or locally advanced rectal cancer (LARC). Neoadjuvant treatments were analysed according to tumour extension, location and age.

Results

Among 463 patients from 27 centres, the most frequent regimen was induction chemotherapy, mainly FOLFIRINOX, followed by long-course chemoradiotherapy (CRT) (65%). This approach was used in 51%, 66% and 71% of patients in the early, intermediate-risk and LARC groups, respectively (p = 0.0060). TNT was more frequently administered for low- than mid-rectal cancers, especially in LARC (86% vs. 71%, p = 0.016). In patients >75 years, CRT + consolidation chemotherapy and radiotherapy alone were proportionally more frequent. Among the early rectal cancers, those treated with induction chemotherapy + CRT had more advanced features than those treated with CRT alone (cT3: 80% vs. 43%, cN+: 62% vs. 10%, tumour size: 3.4 vs. 2.3 cm; all p < 0.001).

Conclusion

TNT with induction chemotherapy is the predominant neoadjuvant approach in French expert centres. Tumour classification, location and patient age significantly influence treatment choices, reflecting a shift towards personalized context-specific care.

目的：随着全新辅助治疗（TNT）、器官保存策略和选择性省略放疗的日益普及，直肠癌的新辅助治疗有了显著的发展。最近的试验支持基于风险的个性化，但其在现实环境中的应用仍然缺乏记录。目的是描述目前法国专家中心中低位直肠癌的新辅助治疗实践，并确定影响决策的肿瘤和患者相关因素。方法：这项观察性研究纳入了距肛门边缘≤10厘米的非转移性直肠腺癌患者，在grecar中心的肿瘤委员会（2022年10月至2023年3月）进行了讨论。肿瘤分为早期、中危或局部晚期直肠癌（LARC）。根据肿瘤范围、部位和年龄分析新辅助治疗方法。结果：在27个中心的463例患者中，最常见的方案是诱导化疗，主要是FOLFIRINOX，其次是长疗程放化疗（CRT）（65%）。早期、中危和LARC组分别有51%、66%和71%的患者采用该方法（p = 0.0060）。TNT更常用于低位直肠癌而非中位直肠癌，尤其是LARC（86%对71%，p = 0.016）。在年龄0 ~ 75岁的患者中，单纯CRT +巩固化疗和放疗的比例更高。在早期直肠癌中，诱导化疗+ CRT治疗的患者比单独CRT治疗的患者具有更多的晚期特征（cT3: 80% vs. 43%, cN+: 62% vs. 10%，肿瘤大小：3.4 vs. 2.3 cm）。结论：TNT联合诱导化疗是法国专家中心主要的新辅助方法。肿瘤分类、位置和患者年龄显著影响治疗选择，反映了向个性化具体情况护理的转变。

{"title":"Contemporary neoadjuvant strategies for rectal cancer: The GRECCAR snapshot study","authors":"Antoine Cazelles, Quentin Denost, Benjamin Fernandez, Michel Rivoire, Hélène Meillat, Philippe Rouanet, Mehdi Karoui, Adeline Germain, Leon Maggiori, Alain Valverde, Nicolas Peru, Eddy Cotte, Etienne Buscail, Jeremie H. Lefevre, Bertrand Trilling, Jean Luc Faucheron, Pierre Yves Sage, Laura Beyer-Berjot, Stephane Benoist, Arnaud Alves, Charles Sabbagh, Jean-Jacques Tuech, Julien Coget, Frédéric Marchal, Guillaume Meurette, Diane Mège, Dahbia Djelil, Simone Manfredelli, Aurélien Venara, Mehdi Ouaissi, Gilles Manceau, French Research Group of Rectal Cancer Surgery (GRECCAR)","doi":"10.1111/codi.70358","DOIUrl":"10.1111/codi.70358","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Neoadjuvant treatment for rectal cancer has evolved markedly with the growing adoption of total neoadjuvant therapy (TNT), organ-preservation strategies and selective omission of radiotherapy. Recent trials support risk-based personalization, but its application in real-world settings remains poorly documented. The aim was to describe current neoadjuvant treatment practices for mid-low rectal cancer in French expert centres and identify tumour- and patient-related factors influencing decisions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>This observational study included patients with non-metastatic rectal adenocarcinoma ≤10 cm from the anal verge, discussed in tumour boards (October 2022 to March 2023) across GRECCAR centres. Tumours were classified as early, intermediate-risk or locally advanced rectal cancer (LARC). Neoadjuvant treatments were analysed according to tumour extension, location and age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 463 patients from 27 centres, the most frequent regimen was induction chemotherapy, mainly FOLFIRINOX, followed by long-course chemoradiotherapy (CRT) (65%). This approach was used in 51%, 66% and 71% of patients in the early, intermediate-risk and LARC groups, respectively (<i>p</i> = 0.0060). TNT was more frequently administered for low- than mid-rectal cancers, especially in LARC (86% vs. 71%, <i>p</i> = 0.016). In patients >75 years, CRT + consolidation chemotherapy and radiotherapy alone were proportionally more frequent. Among the early rectal cancers, those treated with induction chemotherapy + CRT had more advanced features than those treated with CRT alone (cT3: 80% vs. 43%, cN+: 62% vs. 10%, tumour size: 3.4 vs. 2.3 cm; all <i>p</i> < 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>TNT with induction chemotherapy is the predominant neoadjuvant approach in French expert centres. Tumour classification, location and patient age significantly influence treatment choices, reflecting a shift towards personalized context-specific care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10512,"journal":{"name":"Colorectal Disease","volume":"28 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A standardized five-step three-trocar laparoscopic ileocolic resection for Crohn's disease: A 5-year real-life experience from a tertiary IBD centre 克罗恩病的标准化五步三套管针腹腔镜回肠结肠切除术：来自三级IBD中心的5年真实经验

IF 2.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Colorectal Disease

Pub Date : 2026-01-08 DOI: 10.1111/codi.70360

Carlo Alberto Manzo, Giulia De Carlo, Leonardo Lorusso, Caterina Baldi, Gianluca Matteo Sampietro

Background

Surgical management of Crohn‘s disease remains challenging because of disease complexity and substantial variability in operative techniques across centres. Despite the widespread adoption of minimally invasive surgery, laparoscopic ileocolic resection is still characterized by limited technical standardization and heterogeneous perioperative outcomes. Unlike oncological colorectal surgery, inflammatory bowel disease surgery lacks widely accepted, reproducible technical frameworks.

Objective

To describe a standardized five-step, three-trocar laparoscopic ileocolic resection for Crohn‘s disease, aimed at improving reproducibility, safety, and operative efficiency in both elective and emergency settings.

Methods

This technical note details a structured laparoscopic approach based on: (1) systematic intraoperative bowel assessment, (2) a bottom-up medial-to-lateral dissection, (3) mandatory identification of retroperitoneal structures, (4) selective mesenteric division using a ‘clip-and-go’ technique with preservation of the main ileocolic vessels and (5) a standardized intracorporeal isoperistaltic side-to-side anastomosis. The technique is illustrated by a dedicated surgical video, including complex inflammatory scenarios such as thickened mesentery and abscess formation. A consecutive cohort of patients undergoing laparoscopic ileocolic resection for Crohn‘s disease between 2020 and 2025 at a tertiary IBD referral centre was retrospectively analysed.

Results

A total of 110 patients were included. No conversions to open surgery occurred. The mean operative time for isolated ileocolic resection was 116 minutes. The anastomotic dehiscence rate was 2.7%, supporting the feasibility and safety of the standardized laparoscopic workflow in real-life Crohn‘s disease surgery.

Conclusions

The proposed five-step, three-trocar laparoscopic ileocolic resection represents a reproducible and safe technical framework for Crohn‘s disease surgery. This standardized approach may reduce intraoperative variability, facilitate surgical training, and contribute to more consistent perioperative outcomes in inflammatory bowel disease.

背景：克罗恩病的外科治疗仍然具有挑战性，因为疾病的复杂性和各中心手术技术的巨大差异。尽管微创手术已被广泛采用，但腹腔镜回结肠切除术仍存在技术标准化和围手术期预后不均匀的问题。与肿瘤性结直肠手术不同，炎症性肠病手术缺乏广泛接受的可重复的技术框架。目的：描述一种标准化的五步、三套管针腹腔镜回结肠切除术治疗克罗恩病，旨在提高选择性和急诊情况下的重复性、安全性和手术效率。方法：本技术说明详细介绍了一种结构化的腹腔镜方法，该方法基于：(1)系统的术中肠道评估，(2)自下而上的中外侧夹层，(3)腹膜后结构的强制性识别，(4)使用保留主要回肠结肠血管的“夹走”技术进行选择性肠系膜分离，(5)标准化的体内等肠侧对侧吻合。该技术由专门的手术视频演示，包括复杂的炎症情况，如肠系膜增厚和脓肿形成。回顾性分析了2020年至2025年在三级IBD转诊中心接受腹腔镜回肠结肠切除术的克罗恩病患者的连续队列。结果：共纳入110例患者。未发生转开手术。孤立回结肠切除术的平均手术时间为116分钟。吻合口裂开率为2.7%，支持标准化腹腔镜工作流程在现实克罗恩病手术中的可行性和安全性。结论：提出的五步、三套管针腹腔镜回结肠切除术是克罗恩病手术可重复且安全的技术框架。这种标准化的方法可以减少术中变异性，促进手术培训，并有助于炎症性肠病的围手术期结果更加一致。

{"title":"A standardized five-step three-trocar laparoscopic ileocolic resection for Crohn's disease: A 5-year real-life experience from a tertiary IBD centre","authors":"Carlo Alberto Manzo, Giulia De Carlo, Leonardo Lorusso, Caterina Baldi, Gianluca Matteo Sampietro","doi":"10.1111/codi.70360","DOIUrl":"10.1111/codi.70360","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Surgical management of Crohn‘s disease remains challenging because of disease complexity and substantial variability in operative techniques across centres. Despite the widespread adoption of minimally invasive surgery, laparoscopic ileocolic resection is still characterized by limited technical standardization and heterogeneous perioperative outcomes. Unlike oncological colorectal surgery, inflammatory bowel disease surgery lacks widely accepted, reproducible technical frameworks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To describe a standardized five-step, three-trocar laparoscopic ileocolic resection for Crohn‘s disease, aimed at improving reproducibility, safety, and operative efficiency in both elective and emergency settings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This technical note details a structured laparoscopic approach based on: (1) systematic intraoperative bowel assessment, (2) a bottom-up medial-to-lateral dissection, (3) mandatory identification of retroperitoneal structures, (4) selective mesenteric division using a ‘clip-and-go’ technique with preservation of the main ileocolic vessels and (5) a standardized intracorporeal isoperistaltic side-to-side anastomosis. The technique is illustrated by a dedicated surgical video, including complex inflammatory scenarios such as thickened mesentery and abscess formation. A consecutive cohort of patients undergoing laparoscopic ileocolic resection for Crohn‘s disease between 2020 and 2025 at a tertiary IBD referral centre was retrospectively analysed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 110 patients were included. No conversions to open surgery occurred. The mean operative time for isolated ileocolic resection was 116 minutes. The anastomotic dehiscence rate was 2.7%, supporting the feasibility and safety of the standardized laparoscopic workflow in real-life Crohn‘s disease surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The proposed five-step, three-trocar laparoscopic ileocolic resection represents a reproducible and safe technical framework for Crohn‘s disease surgery. This standardized approach may reduce intraoperative variability, facilitate surgical training, and contribute to more consistent perioperative outcomes in inflammatory bowel disease.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10512,"journal":{"name":"Colorectal Disease","volume":"28 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Robotic-assisted excision of a mesorectal sclerosing epithelioid fibrosarcoma in an obese patient: A video vignette 机器人辅助切除肥胖患者的肠系膜硬化上皮样纤维肉瘤：视频片段。

IF 2.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Colorectal Disease

Pub Date : 2026-01-08 DOI: 10.1111/codi.70359

Arcangelo Picciariello, Agnese Dezi, Leonardo Vincenti

引用次数: 0

Correction to ‘ChatGPT as a patient education tool in colorectal cancer—An in-depth assessment of efficacy, quality and readability’ 修正“ChatGPT作为结直肠癌患者教育工具——深入评估其疗效、质量和可读性”。

IF 2.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Colorectal Disease

Pub Date : 2026-01-07 DOI: 10.1111/codi.70367

Siu, A.H., Gibson, D.P., Chiu, C., Kwok, A., Irwin, M., Christie, A., Koh, C.E., Keshava, A., Reece, M., Suen, M. and Rickard, M.J., 2025. ChatGPT as a patient education tool in colorectal cancer—An in-depth assessment of efficacy, quality and readability. Colorectal Disease, 27(1), p. e17267.

In the published article, the authorship contribution was incorrectly stated.

Correct Information: Adrian Siu and Damien Gibson contributed equally and should be recognized as joint first authors.

We apologize for this error.

Siu, a.h., Gibson, d.p., Chiu， C, Kwok， A., Irwin， M., Christie， A., Koh, c.e., Keshava， A., Reece， M., Suen， M.和Rickard， m.j., 2025。ChatGPT作为结直肠癌患者教育工具的疗效、质量和可读性的深入评估结直肠疾病杂志，27(1),p. 1767。在这篇发表的文章中，作者的贡献被错误地写了出来。正确信息：Adrian Siu和Damien Gibson贡献相同，应被视为共同第一作者。我们为这个错误道歉。

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Colorectal Disease

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀